Rituximab associated antibody dysfunction in b cell non-hodgkin's lymphoma
Rituximab is an anti-CD20 chimeric antibody used to treat B cell neoplasms and autoimmune conditions. Although it is well known that rituximab can cause persistent hypogammaglobulinemia, there is no standardized approach to evaluate immune dysfunction in patients treated with rituximab. We characterized immunoglobulin levels and vaccine responses in rituximab-treated B cell non-Hodgkin's lymphoma patients.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: S. Mustafa, A. Ramsey, S. Jamshed Tags: A250 Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan | Vaccines